FOXO earnings analysis
What we found in FOXO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing does not provide current-quarter revenue, margins, EPS, cash flow, balance-sheet totals or quantitative guidance, so period-over-period operating trends cannot be assessed from the supplied text. The principal signals are negative: three previously identified control weaknesses remain, the company has approximately $7.8 million of new senior debt amid defaults and going-concern concerns, and a proposed $3.5 million acquisition requires financing that FOXO does not currently have. The STLA also limits the company’s epigenetics economics and could result in loss of control of FOXO Labs through a 10-year option.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Material weaknesses remain unresolved
- As of June 30, 2026, management concluded that the company’s disclosure controls and procedures were not effective. The filing states that 3 categories of material weaknesses identified in the 2025 Form 10-K continued to exist.
- Preferred stock exchanged for $7.8M debt
- In May 2026, FOXO issued senior unsecured non-convertible promissory notes with aggregate principal of approximately $7.8 million in exchange for 7,775 shares of Series A Preferred Stock, eliminating those preferred shares but increasing debt obligations.
- Potential expansion into 4 collection centers
- FOXO entered an agreement to acquire assets associated with 4 U.S. blood collection centers for $3.5 million in cash at closing, plus a contingent earn-out of up to $1.0 million, subject to licensing, certification, permitting and financing conditions.
- Epigenetics IP monetization agreement
- The May 2026 Strategic Technology License Agreement grants LongevityFP an exclusive worldwide license to FOXO’s epigenetics intellectual property for a royalty of 3% of net revenues, capped at $1.3 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Debt defaults and going-concern risk
- The company states that total debt has increased substantially, many promissory notes are in default, and the approximately $7.8 million senior notes mature on the earlier of May 12, 2027 or an event of default. Cash, working-capital deficits, operating losses and financing dependence raise substantial doubt about going-concern status.
- Acquisition requires unavailable capital
- The proposed blood-center acquisition requires $3.5 million of cash at closing plus up to $1.0 million of earn-out consideration, but FOXO states it does not currently have sufficient capital. The agreement may be terminated if closing has not occurred within 9 months of signing.
- Founder license may reduce IP value and control
- The STLA gives LongevityFP an exclusive, irrevocable 10-year option to acquire majority ownership of FOXO Labs, which could cause FOXO to lose control of the subsidiary. The agreement also limits economics through a 3% royalty on net revenues, capped at $1.3 million, and creates potential conflicts because the counterparty is controlled by the founder.
- Repeated reverse splits signal listing risk
- FOXO effected a 1-for-3,000 reverse stock split on June 30, 2026, its 3rd reverse split since April 2025. The filing warns that the stock price may continue to decline, liquidity may remain limited, and additional reverse splits may be required.
- Settlement-payment defaults
- The company is currently in default on the Illumina settlement, with $723,065 payable in 5 quarterly installments of $144,613, and is also in default under a $90,000 settlement payment schedule with func.media.
- Extreme voting concentration
- Rennova Health holds approximately 99.12% of FOXO’s voting rights as of August 13, 2026. This concentration allows control over stockholder matters and may create conflicts with other stockholders.
What they said about what is next.
No quantitative revenue or EPS guidance was disclosed in the 10-Q; the filing provides no operating outlook or numeric forecast.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- FOXO reported a revenue increase of 63% year-over-year to $5.168 million in Q2 2026, with a narrowed EPS loss of $0.02 across the latest quarter. Significant contributions came from its Healthcare segment, particularly…
- 10-K · April 15, 2026
- FOXO is a small, diversified healthcare and life-sciences company that grew by acquisition (Myrtle on June 14, 2024; RCHI/SCCH on Sept 10, 2024; Vector on Sept 19, 2025) and now reports three operating segments…
- 10-Q · November 10, 2025
- FOXO reported Q3 revenue of $3,548,352 (up 196.6% YoY from $1,196,557 but down 29.0% sequentially from Q2’s ~$5.0M). Gross margin compressed to 41.8% (from 54.8% a year ago) while operating margin improved sharply…
- 10-Q · August 19, 2025
- FOXO reported a strong operational quarter with net revenues of $5,218,373 and income from operations of $567,121 for the three months ended June 30, 2025, driven by higher healthcare operations. Despite operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing FOXO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever